|
Krunal Vishavadia, Sandip Solanki, Hiren Prajapati, Madhu Sharma
Assessment of prescribing practices in overactive bladder pharmacotherapy across different specialties of India: a prescription trend analysis
|
№2 / 2023
|
|
D.V. Ergakov, A.G. Martov
New approaches to combined therapy of irritative symptoms in patients with benign prostatic hyperplasia
|
№2 / 2021
|
|
Z.K. Gadzhieva, E.A. Atamanova
Rationale of efficiency and safety of using beta3-adrenergic receptor agonist for treatment of overactive bladder
|
№4 / 2019
|
|
G.R. Kasyan, S.O. Sukhikh, D.Yu. Pushkar
The place of mirabegron in clinical practice
|
№6 / 2017
|
|
A.S. Kolbin, I.A. Vilyum, M.A. Proskurin, Yu.E. Balykina
Pharmacoeconomic analysis of using mirabegron to treat overactive bladder in the setting of the Russian Federation health care
|
№1 / 2016
|
|
V.V. Romikh, L.Yu. Borisenko, A.V. Zakharchenko
Mirabegron. Whether will be a Revolution in the Pharmacotherapy of Overactive Bladder?
|
№5 / 2015
|
|
G.R. Kasjan
Mirabegron – a New Drug for Treatment of Overactive Bladder
|
№4 / 2015
|
Русский
